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Hemorrhagic Bullous Dermatosis
Bhuvanesh Govind, MD, Luis Eraso, MD, Esteban Gnass, MD, Geno Merli, MD

Figure 1. Hemorrhagic Bullosis Dermatosis. Well-circumscribed,
tense, nontender bullae with no significant surrounding erythema.
Figure 2. Intraepidermal collection of red blood cells, beneath the
keratin layer. (4x power)

The patient is a 64 year old man with active primary central
nervous system B-cell lymphoma who was hospitalized
for management of a right lower extremity traumatic injury
complicated by a calf hematoma. During the hospital
stay, the patient was diagnosed with a provoked left
lower extremity deep vein thrombosis (DVT) and treated
initially with therapeutic dosing of enoxaparin. Five days
after low molecular weight heparin (LMWH) initiation,
gradual development of tense, well-circumscribed bullae
were noted to appear on his arms and hands bilaterally,
ranging from 0.5 cm to 1.5 cm in diameter. These lesions
were both nonpruritic and nontender with no significant
surrounding erythema (Figure 1). Bullae were located
distal to the site of enoxaparin injections. Aside from a
normocytic normochromic anemia related to chronic
medical conditions, results of platelet counts, creatinine
levels, and coagulation profiles remained unremarkable.
A shave biopsy of one of the lesions revealed an intraepidermal collection of red blood cells without evidence
of thrombotic or vasculitic changes (Figures 2 & 3).
enoxaparin dose was reduced several days after lesion
onset due to increasing calf hematoma size, in an effort
to balance anticoagulation benefit for the DVT with risk
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Figure 3. No evidence of thrombotic or vasculitic changes.
Hemorrhagic collection with occasional neutrophils. (210x power)
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of continued bleeding into the hematoma. The bullae
started to regress approximately two weeks after onset,
eventually crusting over. The patient was eventually
discharged home.
We present a case of hemorrhagic bullous dermatosis,
which is a rare type of cutaneous reaction to heparins
with only a handful of cases reported in the literature.
Delayed-type (type IV) hypersensitivity and immunemediated (heparin-induced thrombocytopenia)
mechanisms are the most common causes of cutaneous
complications attributed to heparin products.1 Type IV
cutaneous hypersensitivity reactions are non-antibody
mediated and typically occur several days to weeks
following drug exposure. They may manifest as isolated
or multiple erythematous plaques with papulovesicles
or scaling. Heparin-induced thrombocytopenia, on the
other hand, can induce skin erythema that progresses
to hemorrhage and subsequent tissue necrosis.1 Several
unusual and rare dermatologic manifestations have
been reported in the literature with a broad differential
diagnosis including pustulosis, toxic epidermal
necrolysis, arthus reaction, baboon syndrome, hypereosinophilia, and calcinosis cutis.1,3
There have only been ten cases reported in the
literature regarding the clinical setting and course of
hemorrhagic bullosis. Mechanisms underlying the
pathogenesis of these lesions have not been clearly
elucidated, although a hypersensitivity reaction has
been suspected.1,4,5 The histopathology of the bullae
reveal intraepidermal collections of red blood cells
without any thrombotic or vasculitic changes. Direct
immunofluorescence and heparin platelet factor 4 have
all been negative in prior case reports.4-7 Only one of
the ten cases has reported unfractionated heparin as
an inciting agent for hemorrhagic bullosis,8 while the
remaining have been from LMWH. The age range of
affected patients in case reports were 50-90 years old
with several having a history of malignancy.4-8

heparin therapy with no changes in dosing. Although the
resolution of bullae in our patient occurred several days
after enoxaparin dose reduction, it is hard to differentiate
whether lesion regression occurred directly due to
medication management or the natural history of these
seemingly benign, self-limiting, bullae.
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Hemorrhagic bullosis seems to take a clinically benign
course with no patient report of pain or pruritis. The onset
of bullae in our case is consistent with the reported 5 to
21 day window of lesion development reported in the
literature. The association between lesion regression
and discontinuation of heparin treatment seems to
be unclear given that about half of the patients’ bullae
reported thus far regress despite continuation of
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